FATE
Price
$1.06
Change
+$0.04 (+3.92%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
121.12M
102 days until earnings call
Intraday BUY SELL Signals
TCRX
Price
$1.02
Change
+$0.03 (+3.03%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
56.19M
112 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

FATE vs TCRX

Header iconFATE vs TCRX Comparison
Open Charts FATE vs TCRXBanner chart's image
Fate Therapeutics
Price$1.06
Change+$0.04 (+3.92%)
Volume$26.4K
Capitalization121.12M
TScan Therapeutics
Price$1.02
Change+$0.03 (+3.03%)
Volume$6.7K
Capitalization56.19M
FATE vs TCRX Comparison Chart in %
FATE
Daily Signal:
Gain/Loss:
TCRX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
FATE vs. TCRX commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a Hold and TCRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (FATE: $1.02 vs. TCRX: $0.99)
Brand notoriety: FATE and TCRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FATE: 40% vs. TCRX: 97%
Market capitalization -- FATE: $121.12M vs. TCRX: $58.45M
FATE [@Biotechnology] is valued at $121.12M. TCRX’s [@Biotechnology] market capitalization is $58.45M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FATE’s FA Score shows that 1 FA rating(s) are green whileTCRX’s FA Score has 1 green FA rating(s).

  • FATE’s FA Score: 1 green, 4 red.
  • TCRX’s FA Score: 1 green, 4 red.
According to our system of comparison, both FATE and TCRX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FATE’s TA Score shows that 6 TA indicator(s) are bullish while TCRX’s TA Score has 4 bullish TA indicator(s).

  • FATE’s TA Score: 6 bullish, 5 bearish.
  • TCRX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, FATE is a better buy in the short-term than TCRX.

Price Growth

FATE (@Biotechnology) experienced а -8.93% price change this week, while TCRX (@Biotechnology) price change was -18.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.17%. For the same industry, the average monthly price growth was -5.68%, and the average quarterly price growth was +64.91%.

Reported Earning Dates

FATE is expected to report earnings on Mar 02, 2026.

TCRX is expected to report earnings on Mar 11, 2026.

Industries' Descriptions

@Biotechnology (-2.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($121M) has a higher market cap than TCRX($56.2M). FATE YTD gains are higher at: -38.182 vs. TCRX (-67.431). TCRX has higher annual earnings (EBITDA): -130.55M vs. FATE (-161.6M). FATE (223M) and TCRX (218M) have equal amount of cash in the bank . FATE has less debt than TCRX: FATE (81.3M) vs TCRX (96.7M). FATE has higher revenues than TCRX: FATE (8.47M) vs TCRX (6.96M).
FATETCRXFATE / TCRX
Capitalization121M56.2M215%
EBITDA-161.6M-130.55M124%
Gain YTD-38.182-67.43157%
P/E RatioN/AN/A-
Revenue8.47M6.96M122%
Total Cash223M218M102%
Total Debt81.3M96.7M84%
FUNDAMENTALS RATINGS
FATE: Fundamental Ratings
FATE
OUTLOOK RATING
1..100
53
VALUATION
overvalued / fair valued / undervalued
1..100
12
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
89
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
FATETCRX
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 14 days ago
82%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
FATE
Daily Signal:
Gain/Loss:
TCRX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
REOP53.752.75
+5.39%
Reo Plastics, Inc.
UVRBF1.05N/A
N/A
Universal Robina
CNTHN41.80N/A
N/A
Connecticut Light & Power Co. (The)
IAFNF118.49-0.09
-0.08%
IA FINL CORP INC.
NDTP1.46-0.04
-2.67%
NDT Pharmaceuticals Inc.

TCRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, TCRX has been loosely correlated with FATE. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if TCRX jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TCRX
1D Price
Change %
TCRX100%
+2.07%
FATE - TCRX
40%
Loosely correlated
+4.83%
MGNX - TCRX
39%
Loosely correlated
+2.32%
CGEM - TCRX
38%
Loosely correlated
-2.74%
ELVN - TCRX
37%
Loosely correlated
+3.91%
ZNTL - TCRX
37%
Loosely correlated
+3.41%
More